Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study

Volume: 404, Issue: 2, Pages: 167 - 174
Published: Jan 16, 2019
Abstract
Neoadjuvant therapy (NAT) is increasingly used to improve the prognosis of patients with borderline resectable pancreatic cancer (BRPC) albeit with little evidence of its advantage over upfront surgical resection. We analyzed the prognostic impact of NAT on patients with BRPC in a multicenter retrospective study. Medical data of 165 consecutive patients who underwent treatment for BRPC between January 2010 and December 2014 were collected from...
Paper Details
Title
Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study
Published Date
Jan 16, 2019
Volume
404
Issue
2
Pages
167 - 174
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.